Sera Prognostics (SERA) Stock Analysis

What Sera Prognostics does

Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.

Key metrics

ETFs linked to SERA

Broad-market and Healthcare sector ETFs an investor holding Sera Prognostics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SERA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Sera Prognostics?

Sera Prognostics trades under the ticker SERA on NASDAQ.

Which exchange is SERA listed on?

SERA is listed on NASDAQ.

What sector does Sera Prognostics operate in?

Sera Prognostics is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze SERA in a portfolio?

PortView shows SERA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.